Novo Nordisk recalls GlucaGen HypoKit in US after error at syringe supplier

By Gareth Macdonald contact

- Last updated on GMT

Novo Nordisk recalls GlucaGen HypoKit in US after error at syringe supplier

Related tags: Insulin

Novo Nordisk has recalled six lots of its GlucaGen HypoKit pen in the US after customers in Europe complained of detached needles.

The Danish firm announced the recall last week, explaining the move followed “two customer complaints from the UK and Portugal involving detached needles on the syringe with Sterile Water for Injection (SWFI).”

The GlucaGen HypoKit pen – which has been available in the US since 2005 - is used to deliver a recombinant version of the peptide hormone glucagon. It is used to treat severe hypoglycemia – low blood sugar – in patients with insulin-dependent diabetes.

Novo spokeswoman Mette Kruse Danielsen told us “the root cause was a manufacturing error at the supplier of the glass syringe that is used together with the vial containing freeze dried glucagon​.”

Danielsen also confirmed the device was made by a third party, but declined to name the company involved.

She added that: “Novo Nordisk has in cooperation with the supplier instituted corrective actions to avoid re-occurrence."

Note: Our email newsletter strap line incorrectly stated that the recalled product is an "insulin pen." 

Related topics: Drug Delivery, QA/QC, Delivery technologies

Related news

Show more

Related products

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Follow us

Products

View more

Webinars